Form 4: Intuitive Surgical Executive Exercises and Sells Stock Options Under 10b5-1 Plan
SEC Form 4
Robert DeSantis, EVP & Chief Strategy & Corp Op at Intuitive Surgical, executed multiple transactions involving the exercise of stock options and the sale of common stock under a pre-arranged 10b5-1 trading plan.
Summary
- Robert DeSantis, an executive at Intuitive Surgical, engaged in a series of transactions involving the company's stock on October 25, 2024, October 28, 2024, and October 29, 2024.
- These transactions included the exercise of non-qualified stock options and the subsequent sale of common stock.
- The sales were executed at prices ranging from $506.52 to $514 per share.
- The exercise prices for the options varied, ranging from $208.9 to $347.4167.
- These transactions were conducted under a pre-arranged trading plan that complies with SEC Rule 10b5-1, which is set to expire on December 9, 2024.
- Following these transactions, DeSantis directly owns 5,506 shares of Intuitive Surgical common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The document simply reports stock transactions by an executive under a pre-existing plan. There is no indication of positive or negative sentiment towards the company's performance.
Positives
- The transactions were conducted under a pre-arranged 10b5-1 trading plan, indicating a planned and transparent approach to stock sales.
Future Outlook
The executive's stock sales will continue until the 10b5-1 trading plan expires on December 9, 2024.
Industry Context
Executive stock transactions are common in publicly traded companies and are often scrutinized by investors for insights into management's perspective on the company's future performance. A 10b5-1 plan allows insiders to sell shares over a predetermined period, mitigating concerns about trading on non-public information.
Comparison to Industry Standards
- Executive compensation practices, including stock options, are standard across the medical device industry.
- Companies like Medtronic, Stryker, and Johnson & Johnson also utilize stock options as part of their executive compensation packages.
- The vesting schedules and exercise prices are generally in line with industry norms for incentivizing long-term performance.
Stakeholder Impact
- The stock sales could have a minor impact on shareholders due to the increased supply of shares in the market, but the effect is likely minimal given the relatively small volume of shares sold compared to the company's overall market capitalization.
Key Dates
| Date | Description |
|---|---|
| February 10, 2023 | Date used to measure vesting for some stock options. |
| August 10, 2023 | Date used to measure vesting for some stock options. |
| October 25, 2024 | Date of multiple stock option exercises and sales. |
| October 28, 2024 | Date of multiple stock option exercises and sales. |
| October 29, 2024 | Date of multiple stock option exercises and sales. |
| December 9, 2024 | Expiration date of the 10b5-1 trading plan. |
| August 28, 2029 | Expiration date of some non-qualified stock options. |
| February 27, 2030 | Expiration date of some non-qualified stock options. |
| August 09, 2030 | Expiration date of some non-qualified stock options. |
| February 26, 2031 | Expiration date of some non-qualified stock options. |
| August 26, 2031 | Expiration date of some non-qualified stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.